PD-1/PD-L1 Checkpoint Inhibitors Industry Research Report 2025

Publisher APO Research, Inc.

Published Jul 06, 2025

Length 119 Pages

SKU # APRC20260845

Description

Summary

According to APO Research, the global PD-1/PD-L1 Checkpoint Inhibitors market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for PD-1/PD-L1 Checkpoint Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for PD-1/PD-L1 Checkpoint Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for PD-1/PD-L1 Checkpoint Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of PD-1/PD-L1 Checkpoint Inhibitors include Merck, Junshi Biosciences, Pfizer, Hengrui Pharmaceuticals, Roche, Regeneron Pharmaceuticals, Bristol Myers Squibb and AstraZeneca, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for PD-1/PD-L1 Checkpoint Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1/PD-L1 Checkpoint Inhibitors.

The report will help the PD-1/PD-L1 Checkpoint Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The PD-1/PD-L1 Checkpoint Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PD-1/PD-L1 Checkpoint Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

PD-1/PD-L1 Checkpoint Inhibitors Segment by Company

Merck
Junshi Biosciences
Pfizer
Hengrui Pharmaceuticals
Roche
Regeneron Pharmaceuticals
Bristol Myers Squibb
AstraZeneca
PD-1/PD-L1 Checkpoint Inhibitors Segment by Type

PD-1 Inhibitors
PD-L1 Inhibitors
PD-1/PD-L1 Checkpoint Inhibitors Segment by Application

Gastric Cancer
Squamous Cell Skin Cancer
Melanoma
Non-small Cell Lung Cancer
Other
PD-1/PD-L1 Checkpoint Inhibitors Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1/PD-L1 Checkpoint Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-1/PD-L1 Checkpoint Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1/PD-L1 Checkpoint Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of PD-1/PD-L1 Checkpoint Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of PD-1/PD-L1 Checkpoint Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of PD-1/PD-L1 Checkpoint Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

1 Preface: 1.1 Scope of Report; 1.2 Reasons for Doing This Study; 1.3 Research Methodology; 1.4 Research Process; 1.5 Data Source; 1.5.1 Secondary Sources; 1.5.2 Primary Sources
2 Market Overview: 2.1 Product Definition; 2.2 Global Market Growth Prospects; 2.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size (2020-2031); 2.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales (2020-2031); 2.2.3 Global PD-1/PD-L1 Checkpoint Inhibitors Market Average Price (2020-2031); 2.3 PD-1/PD-L1 Checkpoint Inhibitors by Type; 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million); 2.3.2 PD-1 Inhibitors; 2.3.3 PD-L1 Inhibitors; 2.4 PD-1/PD-L1 Checkpoint Inhibitors by Application; 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031); 2.4.2 Gastric Cancer; 2.4.3 Squamous Cell Skin Cancer; 2.4.4 Melanoma; 2.4.5 Non-small Cell Lung Cancer; 2.4.6 Other
3 Market Competitive Landscape by Manufacturers: 3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Competitive Situation by Manufacturers (2020 Versus 2024); 3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales (K Units) of Manufacturers (2020-2025); 3.3 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue of Manufacturers (2020-2025); 3.4 Global PD-1/PD-L1 Checkpoint Inhibitors Average Price by Manufacturers (2020-2025); 3.5 Global PD-1/PD-L1 Checkpoint Inhibitors Industry Ranking, 2023 VS 2024 VS 2025; 3.6 Global Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Manufacturing Sites & Headquarters; 3.7 Global Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Product Type & Application; 3.8 Global Manufacturers of PD-1/PD-L1 Checkpoint Inhibitors, Established Date; 3.9 Global PD-1/PD-L1 Checkpoint Inhibitors Market CR5 and HHI; 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled: 4.1 Merck; 4.1.1 Merck Company Information; 4.1.2 Merck Business Overview; 4.1.3 Merck PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025); 4.1.4 Merck PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio; 4.1.5 Merck Recent Developments; 4.2 Junshi Biosciences; 4.2.1 Junshi Biosciences Company Information; 4.2.2 Junshi Biosciences Business Overview; 4.2.3 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025); 4.2.4 Junshi Biosciences PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio; 4.2.5 Junshi Biosciences Recent Developments; 4.3 Pfizer; 4.3.1 Pfizer Company Information; 4.3.2 Pfizer Business Overview; 4.3.3 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025); 4.3.4 Pfizer PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio; 4.3.5 Pfizer Recent Developments; 4.4 Hengrui Pharmaceuticals; 4.4.1 Hengrui Pharmaceuticals Company Information; 4.4.2 Hengrui Pharmaceuticals Business Overview; 4.4.3 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025); 4.4.4 Hengrui Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio; 4.4.5 Hengrui Pharmaceuticals Recent Developments; 4.5 Roche; 4.5.1 Roche Company Information; 4.5.2 Roche Business Overview; 4.5.3 Roche PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025); 4.5.4 Roche PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio; 4.5.5 Roche Recent Developments; 4.6 Regeneron Pharmaceuticals; 4.6.1 Regeneron Pharmaceuticals Company Information; 4.6.2 Regeneron Pharmaceuticals Business Overview; 4.6.3 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025); 4.6.4 Regeneron Pharmaceuticals PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio; 4.6.5 Regeneron Pharmaceuticals Recent Developments; 4.7 Bristol Myers Squibb; 4.7.1 Bristol Myers Squibb Company Information; 4.7.2 Bristol Myers Squibb Business Overview; 4.7.3 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025); 4.7.4 Bristol Myers Squibb PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio; 4.7.5 Bristol Myers Squibb Recent Developments; 4.8 AstraZeneca; 4.8.1 AstraZeneca Company Information; 4.8.2 AstraZeneca Business Overview; 4.8.3 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025); 4.8.4 AstraZeneca PD-1/PD-L1 Checkpoint Inhibitors Product Portfolio; 4.8.5 AstraZeneca Recent Developments
5 Global PD-1/PD-L1 Checkpoint Inhibitors Market Scenario by Region: 5.1 Global PD-1/PD-L1 Checkpoint Inhibitors Market Size by Region: 2020 VS 2024 VS 2031; 5.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2020-2031; 5.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2020-2025; 5.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Region: 2026-2031; 5.3 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region: 2020-2031; 5.3.1 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region: 2020-2025; 5.3.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Region: 2026-2031; 5.4 North America PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country; 5.4.1 North America PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2020 VS 2024 VS 2031; 5.4.2 North America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2020-2031); 5.4.3 North America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2020-2031); 5.4.4 United States; 5.4.5 Canada; 5.4.6 Mexico; 5.5 Europe PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country; 5.5.1 Europe PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2020 VS 2024 VS 2031; 5.5.2 Europe PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2020-2031); 5.5.3 Europe PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2020-2031); 5.5.4 Germany; 5.5.5 France; 5.5.6 U.K.; 5.5.7 Italy; 5.5.8 Russia; 5.5.9 Spain; 5.5.10 Netherlands; 5.5.11 Switzerland; 5.5.12 Sweden; 5.5.13 Poland; 5.6 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country; 5.6.1 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2020 VS 2024 VS 2031; 5.6.2 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2020-2031); 5.6.3 Asia Pacific PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2020-2031); 5.6.4 China; 5.6.5 Japan; 5.6.6 South Korea; 5.6.7 India; 5.6.8 Australia; 5.6.9 Taiwan; 5.6.10 Southeast Asia; 5.7 South America PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country; 5.7.1 South America PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2020 VS 2024 VS 2031; 5.7.2 South America PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2020-2031); 5.7.3 South America PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2020-2031); 5.7.4 Brazil; 5.7.5 Argentina; 5.7.6 Chile; 5.8 Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Market Facts & Figures by Country; 5.8.1 Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Market Size by Country: 2020 VS 2024 VS 2031; 5.8.2 Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Sales by Country (2020-2031); 5.8.3 Middle East and Africa PD-1/PD-L1 Checkpoint Inhibitors Revenue by Country (2020-2031); 5.8.4 Egypt; 5.8.5 South Africa; 5.8.6 Israel; 5.8.7 Türkiye; 5.8.8 GCC Countries
6 Segment by Type: 6.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2020-2031); 6.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2020-2031) & (K Units); 6.1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Type (2020-2031); 6.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Type (2020-2031); 6.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Type (2020-2031) & (US$ Million); 6.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Type (2020-2031); 6.3 Global PD-1/PD-L1 Checkpoint Inhibitors Price by Type (2020-2031)
7 Segment by Application: 7.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2020-2031); 7.1.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2020-2031) & (K Units); 7.1.2 Global PD-1/PD-L1 Checkpoint Inhibitors Sales Market Share by Application (2020-2031); 7.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue by Application (2020-2031); 7.2.1 Global PD-1/PD-L1 Checkpoint Inhibitors Sales by Application (2020-2031) & (US$ Million); 7.2.2 Global PD-1/PD-L1 Checkpoint Inhibitors Revenue Market Share by Application (2020-2031); 7.3 Global PD-1/PD-L1 Checkpoint Inhibitors Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market: 8.1 PD-1/PD-L1 Checkpoint Inhibitors Value Chain Analysis; 8.1.1 PD-1/PD-L1 Checkpoint Inhibitors Key Raw Materials; 8.1.2 Raw Materials Key Suppliers; 8.1.3 PD-1/PD-L1 Checkpoint Inhibitors Production Mode & Process; 8.2 PD-1/PD-L1 Checkpoint Inhibitors Sales Channels Analysis; 8.2.1 Direct Comparison with Distribution Share; 8.2.2 PD-1/PD-L1 Checkpoint Inhibitors Distributors; 8.2.3 PD-1/PD-L1 Checkpoint Inhibitors Customers
9 Global PD-1/PD-L1 Checkpoint Inhibitors Analyzing Market Dynamics: 9.1 PD-1/PD-L1 Checkpoint Inhibitors Industry Trends; 9.2 PD-1/PD-L1 Checkpoint Inhibitors Industry Drivers; 9.3 PD-1/PD-L1 Checkpoint Inhibitors Industry Opportunities and Challenges; 9.4 PD-1/PD-L1 Checkpoint Inhibitors Industry Restraints
10 Report Conclusion
11 Disclaimer

Pricing

Currency Rates

Single User Email from Publisher $2,950
Multi User License $4,430
Global Site License Email from Publisher $5,900

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now